专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016029051A1 ASSESSMENT OF HEART FAILURE AND ARRHYTHMIC RISK STRATIFICATION BY MEASURING CIRCULATING HU PROTEINS 审中-公开
标题翻译：通过测量循环HU蛋白来评估心脏衰竭和ARRHYTHMIC风险分析
公开(公告)号：WO2016029051A1
公开(公告)日：2016-02-25
申请号：PCT/US2015/046162
申请日：2015-08-20
申请人： RHODE ISLAND HOSPITAL
发明人： DUDLEY, Samuel
IPC分类号： C40B30/04
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/68 , G01N2800/326 , G01N2800/50 , G01N2800/52
摘要： This invention relates to a diagnostic test measuring circulating HU proteins or gene transcripts in a blood sample to assess arrhythmic risk in heart failure patients. The invention addresses this need and features a diagnostic/prognostic test for measuring circulating HU levels in a sample to assess arrhythmic risk in heart failure patients, alternatively, to determine the risk of SCD. The methods described herein represent a non-invasive (or minimally invasive) test assay. The methods described herein may also include computing a level of an SCN5A variant, or cardiac transcription factors MESP1 (mesoderm posterior posterior protein 1 ), or MEF2C (myocyte enhancer factor-2), or any combination thereof.
摘要翻译：本发明涉及测量血液样品中循环HU蛋白或基因转录物的诊断测试，以评估心力衰竭患者的心律失常风险。本发明解决了这一需求，并且具有用于测量样品中循环HU水平的诊断/预后测试，以评估心力衰竭患者的心律失常风险，或者确定SCD的风险。本文描述的方法代表非侵入性（或微创）测试测定。本文描述的方法还可以包括计算SCN5A变体或心脏转录因子MESP1（中胚层后后蛋白1）或MEF2C（肌细胞增强因子-2）或其任何组合的水平。

2. 发明申请

WO2016012783A1 MARKERS FOR ATRIAL FIBRILLATION (AF) 审中-公开
标题翻译：急性心肌梗死（AF）
公开(公告)号：WO2016012783A1
公开(公告)日：2016-01-28
申请号：PCT/GB2015/052112
申请日：2015-07-22
申请人： THE UNIVERSITY OF BIRMINGHAM
发明人： FABRITZ, Larissa , KIRCHHOF, Paulus
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/326 , G06F19/00 , G06F19/325
摘要： The present invention relates to a method for identifying whether or not it may be appropriate to administer to a subject a therapy for alleviating any potential consequences which may arise due to the subject having an atrial fibrillation (AF), the method comprising detecting, in a sample of fluid from the subject, a level of ccl21 and/or ddit4 expression and determining whether or not it may be appropriate to administer to the subject a therapy for alleviating any consequences which may arise due to the subject having AF, based upon the ccl21 and/or ddit4 expression level detected. Also provided are an anticoagulant or other AF therapy and a method of administering an anticoagulant drug or another AF therapy.
摘要翻译：本发明涉及一种用于鉴定是否适合向受试者施用减轻由于受试者患有心房颤动（AF）可能引起的潜在后果的治疗方法，所述方法包括在来自受试者的液体样本，ccl21和/或ddit4表达的水平，并且基于ccl21确定是否适当地向受试者施用治疗以减轻由于受试者可能产生的任何后果的治疗和/或ddit4表达水平。还提供了抗凝剂或其它AF治疗以及施用抗凝药物或其它AF治疗的方法。

3. 发明申请

WO2014072500A1 TNT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 审中-公开
标题翻译：基于TNT的PAROXYSMAL ATRIAL FIBRILLATION的诊断
公开(公告)号：WO2014072500A1
公开(公告)日：2014-05-15
申请号：PCT/EP2013/073476
申请日：2013-11-11
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
发明人： BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6869 , G01N33/6887 , G01N2333/4712 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/326 , G01N2800/52
摘要： The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being susceptible to anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
摘要翻译：本发明涉及一种诊断近期阵发性房颤的方法。该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（来自受试者的样品中的胰岛素样生长因子结合蛋白7）以及由此确定的量与参考量（参考量）的比较。此外，本发明涉及用于鉴定易于抗凝治疗的受试者的方法。进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

4. 发明申请

WO2013116547A1 IMPLANTABLE DEVICE AND METHODS FOR DIAGNOSING HEART FAILURE USING BIOMARKER PANEL DATA 审中-公开
标题翻译：使用生物标记面板数据诊断心脏失败的可植入设备和方法
公开(公告)号：WO2013116547A1
公开(公告)日：2013-08-08
申请号：PCT/US2013/024189
申请日：2013-01-31
申请人： CARDIAC PACEMAKERS, INC. , STOLEN, Craig, M. , MEDICAL UNIVERSITY OF SOUTH CAROLINA , MEYER, Timothy, E. , SETH, Milan , SPINALE, Francis, G. , WOLD, Nicholas, David
发明人： STOLEN, Craig, M. , MEYER, Timothy, E. , SETH, Milan , SPINALE, Francis, G. , WOLD, Nicholas, David
IPC分类号： A61N1/362 , G01N33/68
CPC分类号： A61B5/14546 , A61B5/14503 , A61B5/4836 , A61B5/686 , A61B5/6869 , A61B5/7282 , A61N1/3627 , A61N1/36557 , A61N1/3956 , G01N33/6893 , G01N2800/32 , G01N2800/325 , G01N2800/326 , G01N2800/50
摘要： Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data and related medical devices and methods, amongst other things. An embodiment can include an implantable medical device including a processor, the implantable medical device configured to diagnose a patient based at least in part on quantified levels of one or more of a panel of biomarkers. The panel of biomarkers including at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. An embodiment can include a method of screening patients. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include analyzing the quantified levels. In an embodiment, the disclosure can include a method of diagnosing a patient. Other embodiments are also included herein.
摘要翻译：本公开的实施例涉及用于利用生物标志物面板数据的系统和方法以及相关的医疗装置和方法。实施例可以包括可植入医疗装置，其包括处理器，所述可植入医疗装置被配置为至少部分地基于面板生物标志物中的一个或多个的量化水平来诊断患者。生物标志物组包括选自CRP，SGP-130，sIL-2R，sTNFR-II，IFNg，BNP，sST2，MMP-2，MMP-9，TIMP-1，TIMP-2， TIMP-4。一个实施方案可以包括筛选患者的方法。该方法可以包括定量患者生物样品中一组或多种生物标志物的水平。该方法还可以包括分析量化水平。在一个实施例中，本公开可以包括诊断患者的方法。本文还包括其它实施例。

5. 发明申请

WO2013057135A1 TROPONIN AND BNP BASED DIAGNOSIS OF RISK PATIENTS AND CAUSE OF STROKE 审中-公开
标题翻译： TROPONIN和BNP基于风险的患者和STROKE的原因的诊断
公开(公告)号：WO2013057135A1
公开(公告)日：2013-04-25
申请号：PCT/EP2012/070553
申请日：2012-10-17
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , HESS, Georg , ZDUNEK, Dietmar , HORSCH, Andrea
发明人： HESS, Georg , ZDUNEK, Dietmar , HORSCH, Andrea
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , G01N33/54306 , G01N33/6893 , G01N2333/47 , G01N2333/4712 , G01N2800/326
摘要： The present invention relates to a method for early differentiating whether a subject suffers from cardioembolic stroke or from non-cardioembolicischemic stroke. The method is based on the determination of the amount of a cardiac Troponin in a sample from a subject suffering from ischemic stroke obtained not more than 24 hours after the onset of symp- toms of ischemic stroke. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及一种用于早期鉴别受试者是否患有心血管卒中或非心脏缺血性卒中的方法。该方法基于在缺血性卒中症状发作后不超过24小时获得的患有缺血性卒中的受试者的样品中心肌肌钙蛋白的量的测定。本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。

6. 发明申请

WO2007143112A3 METHODS FOR DIAGNOSING DISORDERS AND DISEASES ASSOCIATED WITH RYANODINE RECEPTORS AND METHODS FOR IDENTIFYING COMPOUNDS THAT AFFECT RYANODINE RECEPTORS 审中-公开
标题翻译：用于诊断与赖氨酸受体相关的病症和疾病的方法以及鉴定受影响赖氨酸受体的化合物的方法
公开(公告)号：WO2007143112A3
公开(公告)日：2008-03-13
申请号：PCT/US2007012969
申请日：2007-06-01
申请人： UNIV COLUMBIA , MARKS ANDREW ROBERT
发明人： MARKS ANDREW ROBERT
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N33/6896 , G01N2800/10 , G01N2800/28 , G01N2800/2814 , G01N2800/2821 , G01N2800/2878 , G01N2800/32 , G01N2800/325 , G01N2800/326 , G01N2800/34
摘要： The present invention relates to methods for diagnosing disorders and diseases associated with ryanodine receptor function and/or associated with mutations in ryanodine receptors. The present invention also provides methods of indentifying compounds that affect ryanodine receptor function and that may be useful for treating disorders and diseases associated with abnormal or defective ryanodine receptor function, and various other methods. The methods may be performed using samples of peripheral blood, containing lymphocytes, and are therefore far less invasive than methods that involve obtaining samples tissue from other sources.
摘要翻译：本发明涉及用于诊断与兰诺定受体功能相关的疾病和疾病和/或与兰诺定受体突变有关的疾病的方法。本发明还提供鉴定影响兰诺定受体功能的化合物的方法，其可用于治疗与兰诺定受体功能异常或缺陷相关的疾病和疾病以及各种其它方法。所述方法可以使用含有淋巴细胞的外周血样品进行，因此与涉及从其他来源获得样品组织的方法相比，侵入性要小得多。

7. 发明申请

WO2004054436A2 CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 INDUCES ISCHEMIC VENTRICULAR ARRHYTHMIAS AND DECREASES INFARCTION SIZE 审中-公开
标题翻译：钙依赖性磷脂酶A2诱导间质性脑膜炎并减少感染大小
公开(公告)号：WO2004054436A2
公开(公告)日：2004-07-01
申请号：PCT/US2003/040301
申请日：2003-12-15
申请人： WASHINGTON UNIVERSITY IN ST. LOUIS , GROSS, Richard, W.
发明人： GROSS, Richard, W.
IPC分类号： A61B
CPC分类号： G01N33/5088 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , C12Q1/44 , G01N33/92 , G01N2333/918 , G01N2500/04 , G01N2800/326
摘要： A method for evaluating a compound to determine the relative or absolute therapeutic capability of a compound to pharmacologically inhibit ischemia induced activation of iPLA 2 β in an intact myocardium which comprises treating intact myocardium with a compound, inducing ischemia in the myocardium tissue and determining if there has been a change in expression of iPLA 2 β, its activity or in the iPLA 2 β regulating network and determining if there has been a change then that the compound is an anti-arrhythmia or myocardial salvage drug.
摘要翻译：一种用于评价化合物以确定化合物在完整心肌中药理学抑制iPLA2β的缺血诱导的活化的相对或绝对治疗能力的方法，其包括用化合物处理完整心肌，诱导心肌组织中的缺血并确定是否已经 iPLA2beta的表达变化，其活性或iPLA2beta调节网络的变化，并确定是否发生变化，然后该化合物是抗心律失常或心肌抢救药物。

8. 发明申请

WO2015191362A1 METHODS FOR TREATING CARDIOVASCULAR DISEASES 审中-公开
标题翻译：治疗心血管疾病的方法
公开(公告)号：WO2015191362A1
公开(公告)日：2015-12-17
申请号：PCT/US2015/034217
申请日：2015-06-04
申请人： GILEAD SCIENCES, INC.
发明人： FAN, Peidong , KANG, Jong , MIKELS-VIGDAL, Amanda , YAO, Lina , ZHONG, Hongyan
IPC分类号： C07K16/40 , A61K39/395 , G01N33/53 , A61P9/00
CPC分类号： C07K16/40 , A61K2039/505 , A61L31/10 , C07K2317/76 , G01N33/573 , G01N2333/90638 , G01N2800/325 , G01N2800/326
摘要： Provided herein are methods that relate to a novel therapeutic strategy for treatment of heart and/or cardiovascular diseases. The method includes administration of LOXL2 inhibitors for treating, preventing, or ameliorating at least one symptom associated with heart and/or cardiovascular diseases.
摘要翻译：本文提供了涉及用于治疗心脏和/或心血管疾病的新型治疗策略的方法。该方法包括施用LOXL2抑制剂以治疗，预防或改善与心脏和/或心血管疾病相关的至少一种症状。

9. 发明申请

WO2014176562A2 METHODS OF TREATMENT OF CARDIAC ARRHYTHMIAS USING VANOXERINE AND MODIFICATION OF DIET 审中-公开
标题翻译：使用挥发物处理心脏病的方法及其改良
公开(公告)号：WO2014176562A2
公开(公告)日：2014-10-30
申请号：PCT/US2014/035564
申请日：2014-04-25
申请人： CHANRX CORPORATION
发明人： BROWN, Arthur M.
IPC分类号： A61K31/4965 , A61P9/04 , A61P9/00
CPC分类号： A61K31/495 , A23L33/115 , A23V2002/00 , G01N33/9453 , G01N2800/326 , G01N2800/52

10. 发明申请

WO2011158178A1 USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE TREATMENT OF PATIENTS 审中-公开
标题翻译：用于制备用于治疗患者的药物的DRONEDARONE的使用
公开(公告)号：WO2011158178A1
公开(公告)日：2011-12-22
申请号：PCT/IB2011/052575
申请日：2011-06-14
申请人： SANOFI , RADZIK, Davide
发明人： RADZIK, Davide
IPC分类号： A61K31/343 , C07D307/79 , G01N33/84
CPC分类号： A61K31/343 , G01N33/84 , G01N2800/326 , G01N2800/52 , A61K2300/00
摘要： The instant invention relates to a method of determining whether to administer to a patient dronedarone, or a pharmaceutically acceptable salt thereof, in combination with a potassium-depleting diuretic for the treatment of arrhythmia comprising the steps of: i) measuring serum magnesium level in a patient suffering from arrhythmia prior to dronedarone administration to said patient; and ii) initiating dronedarone administration to the patient if the serum magnesium level from step i) is normal.
摘要翻译：本发明涉及一种确定是否给予决奈达隆或其药学上可接受的盐与消耗钾的利尿剂组合用于治疗心律失常的方法，其包括以下步骤：i）测量血清镁水平在决奈达隆给予所述患者之前患有心律失常的患者; 和ii）如果来自步骤i）的血清镁水平正常，则开始给予患者的决奈达隆给药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式